Last Updated : February 26, 2025
Details
FilesGeneric Name:
pasireotide
Project Status:
Active
Therapeutic Area:
Acromegaly, adults
Manufacturer:
Recordati Rare Diseases Canada Inc.
Call for patient/clinician input open:
Brand Name:
Signifor LAR
Project Line:
Reimbursement Review
Project Number:
SR0859-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Signifor LAR (pasireotide for Injectable Suspension) is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Signifor LAR (pasireotide for Injectable Suspension) is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | August 19, 2024 |
|---|---|
| Call for patient/clinician input closed | October 15, 2024 |
| Submission received | October 02, 2024 |
| Submission accepted | October 17, 2024 |
| Review initiated | October 18, 2024 |
| Draft CADTH review report(s) provided to sponsor for comment | January 09, 2025 |
| Deadline for sponsors comments | January 20, 2025 |
| CADTH review report(s) and responses to comments provided to sponsor | February 13, 2025 |
| Expert committee meeting (initial) | February 26, 2025 |
| Draft recommendation issued to sponsor | March 10, 2025 To March 12, 2025 |
| Draft recommendation posted for stakeholder feedback | March 20, 2025 |
| End of feedback period | April 03, 2025 |
Files
Last Updated : February 26, 2025